| |   | And we would be remiss not to note that, as of tomorrow, we will be taking a respite, which is another way of saying our regular menu of interesting items will return on Jan. 3. Meanwhile, we hope you also have an opportunity to break from the usual routine and do something enjoyable. Whatever that may be, though, stay safe. See you next year, as they say … | | | | By Ed Silverman Adobe “This is a clear indication that drug makers are relying less on price increases than they did in the past" said Antonio Ciaccia of 46Brooklyn Read More | | By Ed Silverman Alex Hogan/STAT AbbVie insisted its plan to end discounts for some drugs on Feb. 1 will not disrupt supplies so long as patient claims data is provided. Read More | | By Adam Feuerstein Ryan Pierse/Getty Images Get ready for readouts on Abbvie's cystic fibrosis treatment, Gilead's newly acquired cancer drug Trodelvy, and much more. Read More | | Sponsor content by STAT Events STAT@JPM: Will 2022 bring biotech renewal? Come explore what's happening in biotech, virtually, with STAT's Adam Feuerstein. On Jan. 11, he'll convene experts and reporters to discuss the need-to-know news from biotech's biggest confab, and ask what it all means for the year ahead. | | By Helen Branswell FADEL SENNA/AFP via Getty Images A panel of independent experts that advises the CDC on vaccination policy is expected to discuss the policy change. Read More | | By Peter Arno and Robert Sachs and Kathryn Ardizzone Anne Weston/Francis Crick Institute/Wellcome A petition asking HHS to exercise lawful march-in rights for the prostate cancer drug Xtandi has languished since 2019. It needs action. Read More | |
No comments